Abstract: There is provided a pharmaceutical formulation that is useful in the treatment of myelodysplastic syndrome, comprising a plurality of particles suspended in an aqueous carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 ?m; and (b) comprise solid cores comprising azacitidine, or a pharmaceutically-acceptable salt thereof, coated, at least in part, by a coating of inorganic material comprising mixture of: (i) zinc oxide; and (ii) one or more other metal and/or metalloid oxides, wherein the atomic ratio ((i):(ii)) is between at least 1:6 and up to and including about 6:1. Said mixed oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. The formulation may provide for the delayed or sustained release of azacitidine to treat myelodysplastic syndrome without a burst effect.

Abstract: Disclosed is a therapeutic regimen which includes S-adenosyl methionine, or a salt thereof; folic acid, or a metabolite thereof, or a salt thereof; and a compound of Formula (1), or salt thereof, useful in the treatment of a variety of conditions, e.g., neuropsychiatric conditions such as depression. The therapeutic regimen may be used in combination with one or more therapeutic agents as described here.

Abstract: This disclosure provides compositions and methods for stimulating the innate immune response in a subject with agents capable of stimulating an innate immune response in a subject upon administration to the subject. In particular, the present invention is directed to crystalline polymorphic forms (e.g. coordinate polymeric forms) of STING agonists associated (e.g. mixed) with one or more metal ions (e.g., Zn2+, Mn2+, Al3+, Fe3+, Cu2+), as well as systems and methods utilizing such compositions (e.g., in therapeutic settings).

Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

Abstract: Darbepoetin alpha treats anemia and it is traditionally manufactured using recombinant Chinese Hamster Ovary cells, a complex and expensive process; this invention reports an mRNA composition that encodes darbepoetin alpha in vivo as a therapeutic protein.

Abstract: An immuno-oncology therapeutic composition containing, as an active ingredient, an adjuvant including lipopeptides and poly (I:C) provided in one aspect of the present invention can induce a large therapeutic effect on a variety of carcinomas, and can be effectively used for anticancer therapy by significantly enhancing anticancer effects through combined administration with conventional anticancer drugs, such as chemical anticancer drugs, anticancer vaccines, and immune checkpoint inhibitors, having different mechanisms.

Abstract: A hypertension preload treatment formulation for limiting ingested sodium from entering the bloodstream and method of using the same. The hypertension preload treatment formulation is provided in an oral dosage from. The hypertension preload treatment formulation comprises a therapeutically effective dosage of a sodium-binding agent and an excipient. The sodium-binding agent is a resin comprising a polystyrene cross-linked chain structure formulated to sequestering sodium cations in the resin for later excretion. Methods of binding dietary sodium and treating or preventing hypernatremia in a hypertensive patient are also provided.

Abstract: The invention relates to silicon particles for use in therapy, wherein said silicon particles are prepared via chemical vapor deposition (CVD).

Abstract: Methods for administering nitric oxide (NO) generated by a plasma source via stream of gas also containing a number of other chemical and physical components that create synergistic effect in treatment of a variety of medical conditions. A stream of gas is generated by a plasma source/sources, in which nitric oxide is a part of its content and in desired concentration and at the appropriate speed, so that therapeutically significant amount of NO is delivered per unit of treated tissue area and per unit of time. The stream also contains other physical and chemical compounds such as H2O2, OH, O2, O2? (i.e., oxygen superoxide), heating and UV radiation. The stream of gas generated by plasma source(s) must be precisely directed to the site of action to achieve the best therapeutic result.

Abstract: Provided herein are formulations comprising sodium thiosulfate. Also provided herein are methods of treating, preventing or ameliorating a sulfur mustard skin injury in a subject, wherein the methods comprise contacting the subject with a formulation provided herein.

Abstract: Provided is an antibacterial composition containing transition metal dichalcogenide (TMD) as an active ingredient and a method comprising: adding bulk TMD to a polyacrylic acid (PAA) solution to prepare a mixed solution; ultrasonically treating the mixed solution; centrifuging the ultrasonically treated mixed solution to obtain a precipitate from a supernatant; and redispersing the precipitate in water and centrifuging the same to obtain a PAA-TMD nanosheet from the supernatant.

Abstract: Described are methods of producing an autologous composition useful for treatment of damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory disorders in a mammal. The method comprises preparing an anti-inflammatory/anti-catabolic component of the autologous composition comprising IL-1ra and TIMPs. An anti-inflammatory/anti-catabolic component is prepared comprising: collecting blood from the mammal; delivering the blood to a tube; incubating the blood at a temperature of from about 37° C. to about 39° C. for about 24 hours, preferably in the presence of sodium citrate; centrifuging the blood to separate the blood into a supernatant component and a cellular fraction; and collecting the supernatant component.

Abstract: Compositions, methods of treatment for liver disease such as liver fibrosis, compositions, and methods for the manufacture thereof, comprising a plurality of macrophages derived from human induced pluripotent stem cells (iPSCs), wherein the macrophages are polarized to a pro-inflammatory M1 phenotype and/or an anti-inflammatory M2 phenotype. Administration reduces fibrogenic gene expression and liver disease associated histological markers. The M1 macrophages express elevated CD80, TNF-? and IL-6. The M2 macrophages express elevated CD206, CCL17, and CCL22.

Abstract: The present invention relates to the combination of a T cell receptor (TCR) specific for the FRAME peptide SLLQH-LIGL and a chimeric co-stimulatory receptor comprising an extracellular domain derived from PD-1(CD279) and an intracellular domain derived from 4-1BB (CD137). In particular, the invention refers to a cell comprising said TCR and chimeric co-stimulatory protein. Further the invention refers to a nucleic acid encoding the TCR and the co-stimulatory receptor, a corresponding vector and a corresponding nucleic acid composition. Moreover, the invention relates to the according pharmaceutical composition. Accordingly the invention also relates to the cell and the nucleic acid constructs for use as a medicament, in particular to the TCR for use in the treatment of cancer.

Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically birnds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.

Abstract: The present invention regards methods and/or compositions related to Natural Killer T cells that are engineered to harbor an expression construct that encodes IL-2, IL-4, IL-7, and/or IL-15 and additionally or alternatively comprise a chimeric antigen receptor (CAR).

Abstract: Provided herein are acute myeloid leukemia antigen targets for chimeric receptors and methods of using same.

Abstract: Described herein are immunoresponsive cells engineered to express cytokines, chimeric receptors, and synthetic transcription factor systems. Also described herein are nucleic acids, cells, and methods directed to the same.

Abstract: The present invention relates to uses of and methods of using activators of Nrf2 to enhance natural killer (NK) cell and/or T cell activity and/or survival, particularly in response to stress. The NK cells and/or T cells can be utilised in the treatment of cancer via enhanced cell therapy.

Abstract: Compositions comprising one or more peptide fragments of preproinsulin for treating type 1 diabetes mellitus (T1DM) autoimmunity, methods of treating T1DM autoimmunity using such compositions, and kits comprising such compositions for diagnosing and/or treating TIDM autoimmunity.

Abstract: A preparation and an application of a chimeric antigen receptor immune cell constructed on the basis of a C-type lectin superfamily low-density lipoprotein receptor (LOX1) are provided. Specifically provided is a chimeric antigen receptor (CAR) modified on the basis of LOX1. The CAR contains an extracellular binding domain capable of specifically targeting LOX1 receptors such as heat shock protein, oxidized low-density lipoprotein (oxLDL) and phosphatidylserine. The CAR immune cell has strong specificity and target affinity, and therefore has strong target cell killing capability and a high degree of safety.

Abstract: The present disclosure relates to compositions and methods of uses of a monoallelic MHC-expressing cell line, as well as method of identifying a neoepitope-MHIC binding pair and methods of treating a subject having a cancer or tumor expressing a neoantigen and a MHC allele.

Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

Abstract: The present invention relates to: a composition and a kit for preventing, alleviating or treating atopic dermatitis, comprising primed function-enhanced stem cells and regulatory T cells; and a method for preventing, alleviating or treating atopic dermatitis by using same. When function-enhanced stem cells, of the present invention, treated with TNF-?, IFN-? and IFN-? or TNF-?, IFN-?, IFN-? and vitamins are treated in combination with regulatory T cells, the imbalance of Th1/Th2 cells of an atopic dermatitis patient can be alleviated and the status of the atopic dermatitis patient can be shifted to Th1, and thus the present invention can be widely used in various fields of prevention, alleviation or treatment of atopic dermatitis.

Abstract: The present invention relates to the field of medicine, in particular to internal and aesthetic regenerative medicine. More specifically, the present invention relates to a composition suitable for use as a transport medium for adipose tissue and/or cells derived thereof. The invention further relates to a liposuction infiltration formulation and a process to obtain lipoaspirate material.

Abstract: A composition comprising a cell population wherein the population is suitable for transplantation into a subject in need thereof, and characterized by differences of expression levels of a plurality of genes. Further, methods and kits for identifying a cell population suitable for transplantation into a subject in need thereof.

Abstract: The present invention relates to the pharmaceutical use of a cord blood immunosuppressive cell and, more specifically, the present invention provides the use of a human-derived cord blood immunosuppressive cell, which is selected in accordance with analysis of function and phenotype and a classification standard, as a new cell therapy product for anti-inflammation, anti-fibrosis, and prevention or treatment of myocardial infarction.

Abstract: Disclosed herein are compositions and methods related to isolated cells (e.g., isolated stem cells) comprising a disruption in the 3?-UTR of an immunosuppressor, cells differentiated from such stem cells (e.g., pancreatic islet cells or immune cells) and methods of using the cells to treat diseases (e.g., diabetes or cancer). Methods of producing (i.e., genetically modifying) the isolated cells (e.g., isolated stem cells) are also provided.

Abstract: A method for treating or preventing nociceptive pain by administering an ethanol extract of Brazilian green propolis and compositions comprising this extract.

Abstract: Disclosed herein are methods for treating cancer by administering an immune checkpoint inhibitor and modifying an amount of one or more bacteria in an intestine of the subject.

Abstract: A probiotic based skin care nutraceutical composition comprising human friendly intestinal microbes and a grow medium having pomegranate extract comprising Punicalagins, Ellagitannin, Punicic acid, Ellagitannis, wherein the microbes reaching inside human body to create an ambient environment for these friendly microbes to live and multiply in human body to kick start and activate cellular and molecular regenerative factors that activates producing Urolithin A in good quantity and in natural way, create the telomerase enzyme in optimal, create optimal level of nitric oxide inside human body, secrete collagen 17, stimulate glutathione enzyme level naturally and erase of free radicals of contaminated facial skin cell, activates facial endogenous stem cells ER internally efficiently in natural way to act as a skin progenitor for new facial skin regeneration.

Abstract: Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individual's microbiome to reduce the likelihood of osteoporosis.

Abstract: Provided are methods of increasing ursodeoxycholic acid (UDCA) levels in a mammalian subject. The methods comprise orally administering to the mammalian subject a composition comprising one or more bacterial strains in an amount effective to increase UDCA levels in the mammalian subject. Also provided are methods of antagonizing farnesoid X receptor (FXR) in intestinal cells of a mammalian subject. Such methods comprise orally administering to the mammalian subject a composition comprising one or more bacterial strains in an amount effective to antagonize FXR in intestinal cells of the mammalian subject. In certain embodiments, the mammalian subject has diabetes, e.g., type 2 diabetes. According to some embodiments, the mammalian subject suffers from a liver disorder, obesity, or both. In certain embodiments, the mammalian subject has colorectal cancer. According to some embodiments, the mammalian subject has gallstones.

Abstract: The present disclosure is directed towards skin care compositions and methods for providing treatment of scalp disorders. More specifically, the present disclosure is directed towards methods and compositions comprising at least one microorganism of the genus Yarrowia, and/or a cell lysate thereof, and/or a fermentate thereof, and/or a metabolite thereof in combination with at least one Bacillus velezensis, and/or a cell lysate thereof, and/or fermentate thereof, and/or a metabolite thereof, for treating a scalp disorder, including dandruff.

Abstract: Provided herein is a technology whereby a heterologous protein can be expressed in a bacterium which does not have an endogenous Tat system secretion machine. The present specification discloses a bacterium such as bifidobacteria, lactococci, and staphylococci which has been modified to express a heterologous Tat protein. The bacterium has the ability to produce and secrete a heterologous protein.

Abstract: The present disclosure discloses a strain of highly organic zinc-enriched Bifidobacterium animalis capable of promoting growth and reproductive development, belonging to the technical field of microorganisms. The B. animalis CCFM1230 screened by the present disclosure can efficiently enrich inorganic zinc and convert same into organic zinc, which is better absorbed and utilized by organisms, and effectively promotes growth and reproductive development. Animal experiments have proved that zinc-rich B. animalis can promote the growth and reproductive development of male rat pups, exert higher biological activity than inorganic zinc, and meet the physiological requirements of zinc supplementation. According to the present disclosure, the B. animalis CCFM1230 can efficiently enrich inorganic zinc for the preparation of a probiotic preparation capable of promoting growth and reproductive development, and thus has great application prospects in the field of food or medicine.

Abstract: The present invention relates to a composition for preventing or treating inflammatory bowel disease. More specifically, the present invention provides a pharmaceutical composition and a health food composition for preventing or treating inflammatory bowel disease, comprising, as active ingredients, two or more strains selected from the group consisting of Tetragenococcus halophilus, Eubacterium rectale and Lactobacillus animalis; and cultures of the strains, concentrates of the cultures, extracts of the cultures, or lysates thereof. The composition comprises two or more strains having anti-inflammatory activity as an active ingredient and regulates immune cells related to inflammatory bowel disease, thereby preventing, ameliorating or treating inflammatory bowel disease more effectively than a single strain.

Abstract: The present disclosure relates to compositions and methods useful for dietary augmentation to provide therapeutic intervention for the treatment and management of acne-prone skin. According to one embodiment of the present disclosure, there is provided an orally administrable composition containing a therapeutically effective amount of: (a) a probiotic blend of bacterial components containing at least: (i) Lactobacillus acidophilus, (ii) Bifidobacterium lactis, an (iii) Bacillus coagulans; (b) guggul; and (c) green tea leaf.

Abstract: Disclosed is a composition containing a Lactobacillus fermentum strain, preferably a composition containing Lactobacillus fermentum GB-102 strain deposited with accession number KCTC 14105BP and natural killer cells, and the use of the strain for administration in combination with natural killer cells for the suppression of weight gain or the prevention and/or treatment of metabolic diseases, and the composition and the combination therapy have an effect of remarkably suppressing weight gain. The composition and the combination therapy can be easily used to control the body weight of a subject, and are useful in the fields of beauty, livestock, medicines, and the like, in particular, are useful in the fields of pharmaceutical compositions, food additives, health functional foods, and therapeutic agents for ameliorating, preventing and treating metabolic diseases including obesity.

Abstract: The present invention provides evidence that administration of a probiotic product to newborn piglets and during suckling makes the piglets more resilient towards an ETEC challenge post-weaning and after cessation of the probiotic administration. The pigs administered with probiotics pre-weaning were faster at overcoming the ETEC infection by which ETEC counts in feces were significantly faster reduced compared with non-probiotic supplemented pigs.

Abstract: The present disclosure relates to compositions and methods useful for dietary augmentation to provide therapeutic intervention for the treatment and management of acne-prone skin. According to one embodiment of the present disclosure, there is provided an orally administrable composition containing a therapeutically effective amount of: (a) a probiotic blend of bacterial components containing at least: (i) Lactobacillus acidophilus, (ii) Bifidobacterium lactis, an (iii) Bacillus coagulans; (b) guggul; and (c) green tea leaf.

Abstract: Disclosed herein is a recombinant baculovirus for producing an alphavirus virus-like replicon particle (VRP) having an exogenous gene in a mosquito cell. Said recombinant baculovirus comprises: (1) a replicon comprising a first promoter, and a first polynucleotide encoding at least one alphavirus non-structural protein and is operably linked to the first promoter; and (2) a helper comprising a second promoter, and a second polynucleotide encoding at least one alphavirus structural protein and is operably linked to the second promoter; wherein, the helper is upstream or downstream to the replicon; and the first promoter is less effective than the second promoter in driving gene expression in the mosquito cell. Also encompassed in the present disclosure are methods for detecting an antibody against an alphavirus in a biological sample, and/or screening an antiviral agent suitable for treating an alphavirus infection, with the aid of the alphavirus VRP produced by the present recombinant baculovirus.

Abstract: Recombinantly-modified Cutibacterium acnes-specific bacteriophage, and recombinantly modified bacteriophage-derived endolysin enzyme are provided. Such compositions, alone or in combination with other antimicrobial agents or immunomodulators, may be used in pharmaceutical compositions, particularly pharmaceutical compositions to treat acne, promote wound healing, inhibit the growth of biofilms and to decrease the likelihood of, prevent or treat surgical related infections. The present invention is particularly directed to such formulations that are compounded for topical administration to a subject or used for application to medical devices. In particular, such pharmaceutical compositions may be compounded for topical administration to a subject, or compounded for application to a medical device.

Abstract: The present disclosure relates to an oncolytic virus and methods of using such to treat cancer. The methods may advantageously involve further treating with at least a first DNA damaging agent, such as radiation or a chemotherapeutic agent. In some embodiments, the oncolytic virus is an oncolytic herpes simplex virus (oHSV) that optionally has been engineered to expression a portion of CD44, in particular the extracellular domain of CD44.

Abstract: The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.

Abstract: The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.

Abstract: The disclosure provides compounds with nitrile warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with nitrile warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.

Abstract: The disclosure features methods for inhibiting RAS proteins. The disclosure also contains methods for the treatment of cancer.

Abstract: A method for treating or preventing a neovascular eye disease including: administering a patient in need thereof a pharmaceutical composition including a polypeptide, the peptide having an amino acid sequence I or II; I: FPGSDRF (SEQ ID NO: 1)-Z; II: X-FPGSDRF (SEQ ID NO: 1)-Z; S represents phosphorylated serine; X and Z independently represents an amino acid or an amino acid sequence; X is selected from F, (R)9 (SEQ ID NO: 2), (R)9-F (SEQ ID NO: 3), 6-aminohexanoic acid, 6-aminohexanoic acid-F, 6-aminohexanoic acid-(R)9 (SEQ ID NO: 2), 6-aminohexanoic acid-(R)9-F (SEQ ID NO: 3); and Z is selected from (G)n-RGD or A-(G)n-RGD (SEQ ID NO: 4), where n is an integer greater than or equal to 0, in the range of 0-10.

Abstract: Disclosed herein are cyclosporine compounds and methods for use in the treatment, prevention, or amelioration of glucose intolerance, wherein the compounds inhibit the activity of N-formyl peptide receptor 1 (FPR1).